Trials / Completed
CompletedNCT04122911
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temozolomide | pharmacological |
Timeline
- Start date
- 2017-01-29
- Primary completion
- 2017-12-30
- Completion
- 2019-12-16
- First posted
- 2019-10-10
- Last updated
- 2020-10-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04122911. Inclusion in this directory is not an endorsement.